Company · CIK 0001423824 · SIC 2834 — Pharmaceutical Preparations
ALDER BIOPHARMACEUTICALS INC · ALDR
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| May 20, 2016 SForm 4 → | May 24, 8:13 pm EDT | Randall C SchatzmanPresident and CEO, Director | 10,000 | $28.02 | $280,175 | 112,947 | −8.13% | plan? |
| May 20, 2016 MForm 4 → | May 24, 8:13 pm EDT | Randall C SchatzmanPresident and CEO, Director | 10,000 | $1.27 | $12,650 | 116,964 | — | plan? |
| Apr 14, 2016 SForm 4 → | Apr 18, 6:40 pm EDT | Randall C SchatzmanPresident and CEO, Director | 30,000 | $28.07 | $841,967 | 112,947 | −21.0% | plan? |
| Apr 14, 2016 MForm 4 → | Apr 18, 6:40 pm EDT | Randall C SchatzmanPresident and CEO, Director | 30,000 | $0.6783 | $20,350 | 117,461 | — | plan? |
| Jan 4, 2016 SForm 4 → | Jan 6, 8:40 pm EST | Mark James LittonChief Business Officer | 25,000 | $31.40 | $784,951 | 73,718 | −25.3% | plan? |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:40 pm EST | Mark James LittonChief Business Officer | 25,000 | $0.385 | $9,625 | 98,718 | — | plan? |
| Jan 4, 2016 SForm 4 → | Jan 6, 8:37 pm EST | John A LathamChief Scientific Officer | 10,000 | $31.41 | $314,137 | 241,726 | −3.97% | plan? |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:37 pm EST | John A LathamChief Scientific Officer | 10,000 | $1.27 | $12,650 | 251,726 | — | plan? |
| Jan 4, 2016 SForm 4 → | Jan 6, 8:35 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $31.47 | $314,747 | 111,579 | −8.23% | plan? |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:35 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $0.385 | $3,850 | 121,579 | — | plan? |
| Dec 1, 2015 SForm 4 → | Dec 3, 9:02 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 4,272 | $37.24 | $159,104 | 0 | −100% | plan? |
| Dec 1, 2015 MForm 4 → | Dec 3, 9:02 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 4,272 | $0.385 | $1,645 | 4,272 | — | plan? |
| Dec 1, 2015 SForm 4 → | Dec 3, 9:00 pm EST | John A LathamChief Scientific Officer | 4,550 | $37.24 | $169,452 | 241,726 | −1.85% | plan? |
| Dec 1, 2015 MForm 4 → | Dec 3, 9:00 pm EST | John A LathamChief Scientific Officer | 4,550 | $0.385 | $1,752 | 246,276 | — | plan? |
| Dec 1, 2015 SForm 4 → | Dec 3, 8:59 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $37.24 | $372,431 | 111,579 | −8.23% | plan? |
| Dec 1, 2015 MForm 4 → | Dec 3, 8:59 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $0.385 | $3,850 | 121,579 | — | plan? |
| Nov 30, 2015 AForm 4 → | Feb 2, 2016, 7:00 pm EST | Larry BenedictSr. VP Finance | 2,000 | $8.50 | $17,000 | 28,247 | — | plan? late |
| Nov 30, 2015 SForm 4 → | Dec 2, 5:56 pm EST | Stephen M DowDirector | 88 | $37.11 | $3,266 | 0 | −100% | plan? |
| Nov 2, 2015 SForm 4 → | Nov 4, 9:44 pm EST | John A LathamChief Scientific Officer | 4,545 | $33.69 | $153,137 | 241,265 | −1.85% | plan? |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:44 pm EST | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 245,810 | — | plan? |
| Nov 2, 2015 SForm 4 → | Nov 4, 9:42 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $33.67 | $131,299 | 0 | −100% | plan? |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:42 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Nov 2, 2015 SForm 4 → | Nov 4, 9:40 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $33.71 | $337,066 | 109,921 | −8.34% | plan? |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:40 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | $0.385 | $3,850 | 119,921 | — | plan? |
| Oct 31, 2015 JForm 4 → | Nov 3, 5:59 pm EST | Gary BridgerDirector | 3,469,528 | — | — | 0 | — | plan? |
| Oct 1, 2015 SForm 4 → | Oct 5, 6:21 pm EDT | John A LathamChief Scientific Officer | 4,545 | $32.26 | $146,603 | 241,265 | −1.85% | plan? |
| Oct 1, 2015 MForm 4 → | Oct 5, 6:21 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 245,810 | — | plan? |
| Oct 1, 2015 SForm 4 → | Oct 5, 6:19 pm EDT | Mark James LittonChief Business Officer | 7,500 | $32.27 | $242,002 | 72,919 | −9.33% | plan? |
| Oct 1, 2015 SForm 4 → | Oct 5, 6:16 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $32.25 | $125,778 | 0 | −100% | plan? |
| Oct 1, 2015 MForm 4 → | Oct 5, 6:16 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:19 pm EDT | Larry BenedictSr. VP Finance | 24,981 | $3.28 | $82,060 | 26,247 | — | plan? |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:14 pm EDT | John A LathamChief Scientific Officer | 31,818 | $0.99 | $31,500 | 241,265 | — | plan? |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:11 pm EDT | Mark James LittonChief Business Officer | 12,764 | $1.27 | $16,146 | 80,419 | — | plan? |
| Sep 1, 2015 SForm 4 → | Sep 3, 6:09 pm EDT | John A LathamChief Scientific Officer | 4,545 | $38.52 | $175,059 | 209,447 | −2.12% | plan? |
| Sep 1, 2015 MForm 4 → | Sep 3, 6:09 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,992 | — | plan? |
| Sep 1, 2015 SForm 4 → | Sep 3, 6:01 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $38.50 | $150,165 | 0 | −100% | plan? |
| Sep 1, 2015 MForm 4 → | Sep 3, 6:01 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Aug 31, 2015 SForm 4 → | Sep 2, 2:51 pm EDT | SRB Associates IX L.P. +2Other | 16,218 | $38.75 | $628,460 | 88 | −99.5% | plan? |
| Aug 31, 2015 SForm 4 → | Sep 2, 2:51 pm EDT | Stephen M DowDirector | 16,218 | $38.75 | $628,460 | 282,278 | −5.43% | plan? |
| Aug 12, 2015 JForm 4 → | Aug 13, 7:51 pm EDT | SRB Associates IX L.P. +2Other | 1,795,794 | — | — | 88 | — | plan? |
| Aug 12, 2015 JForm 4 → | Aug 13, 7:50 pm EDT | John V Jaggers +7Other | 1,818,668 | — | — | 4,458 | — | plan? |
| Aug 12, 2015 JForm 4 → | Aug 13, 7:49 pm EDT | Stephen M DowDirector | 1,803,904 | — | — | 298,496 | — | plan? |
| Aug 11, 2015 SForm 4 → | Aug 13, 7:51 pm EDT | SRB Associates IX L.P. +2Other | 212,467 | $40.23 | $8,548,172 | 1,811,970 | −10.5% | plan? |
| Aug 11, 2015 SForm 4 → | Aug 13, 7:50 pm EDT | John V Jaggers +7Other | 212,467 | $40.23 | $8,548,172 | 1,812,016 | −10.5% | plan? |
| Aug 11, 2015 SForm 4 → | Aug 13, 7:49 pm EDT | Stephen M DowDirector | 212,467 | $40.23 | $8,548,172 | 2,086,096 | −9.24% | plan? |
| Aug 3, 2015 SForm 4 → | Aug 5, 6:27 pm EDT | John A LathamChief Scientific Officer | 4,545 | $45.62 | $207,322 | 209,447 | −2.12% | plan? |
| Aug 3, 2015 MForm 4 → | Aug 5, 6:27 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,992 | — | plan? |
| Aug 3, 2015 SForm 4 → | Aug 5, 6:26 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $45.64 | $178,003 | 0 | −100% | plan? |
| Aug 3, 2015 MForm 4 → | Aug 5, 6:26 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Jul 1, 2015 SForm 4 → | Jul 6, 6:05 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $51.18 | $199,616 | 0 | −100% | plan? |
| Jul 1, 2015 MForm 4 → | Jul 6, 6:05 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Jul 1, 2015 SForm 4 → | Jul 6, 6:02 pm EDT | John A LathamChief Scientific Officer | 4,545 | $51.13 | $232,381 | 209,447 | −2.12% | plan? |
| Jul 1, 2015 MForm 4 → | Jul 6, 6:02 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,992 | — | plan? |
| Jul 1, 2015 SForm 4 → | Jul 6, 5:59 pm EDT | Mark James LittonChief Business Officer | 7,500 | $51.10 | $383,219 | 67,655 | −9.98% | plan? |
| Jun 12, 2015 SForm 4 → | Jun 16, 6:15 pm EDT | Larry BenedictSr. VP Finance | 25,454 | $47.46 | $1,208,090 | 1,266 | −95.3% | plan? |
| Jun 12, 2015 MForm 4 → | Jun 16, 6:15 pm EDT | Larry BenedictSr. VP Finance | 25,454 | $1.65 | $41,999 | 26,720 | — | plan? |
| Jun 4, 2015 SForm 4 → | Jun 8, 7:05 pm EDT | Mark James LittonChief Business Officer | 25,000 | $44.27 | $1,106,853 | 75,155 | −25.0% | plan? |
| Jun 4, 2015 MForm 4 → | Jun 8, 7:05 pm EDT | Mark James LittonChief Business Officer | 25,000 | $0.385 | $9,625 | 100,155 | — | plan? |
| Jun 4, 2015 SForm 4 → | Jun 8, 7:03 pm EDT | John A LathamChief Scientific Officer | 25,000 | $44.18 | $1,104,463 | 209,447 | −10.7% | plan? |
| Jun 4, 2015 MForm 4 → | Jun 8, 7:03 pm EDT | John A LathamChief Scientific Officer | 25,000 | $0.385 | $9,625 | 234,447 | — | plan? |
| Jun 4, 2015 JForm 4 → | Jun 8, 6:09 pm EDT | Stephen M DowDirector, 10% Owner | 8,962 | — | — | 2,298,563 | — | plan? |
| Jun 4, 2015 JForm 4 → | Jun 8, 6:08 pm EDT | John V Jaggers +710% Owner | 25,276 | — | — | 2,340 | — | plan? |
| Jun 4, 2015 JForm 4 → | Jun 8, 6:08 pm EDT | SRB Associates IX L.P. +210% Owner | 2,024,529 | — | — | 46 | — | plan? |
| Jun 1, 2015 SForm 4 → | Jun 3, 8:04 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $41.53 | $161,969 | 0 | −100% | plan? |
| Jun 1, 2015 MForm 4 → | Jun 3, 8:04 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Jun 1, 2015 SForm 4 → | Jun 3, 7:59 pm EDT | John A LathamChief Scientific Officer | 4,545 | $41.53 | $188,757 | 209,447 | −2.12% | plan? |
| Jun 1, 2015 MForm 4 → | Jun 3, 7:59 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,992 | — | plan? |
| May 26, 2015 SForm 4 → | May 28, 6:15 pm EDT | Randall C SchatzmanPresident and CEO, Director | 50,000 | $38.96 | $1,948,085 | 109,921 | −31.3% | plan? |
| May 26, 2015 MForm 4 → | May 28, 6:15 pm EDT | Randall C SchatzmanPresident and CEO, Director | 50,000 | $0.385 | $19,250 | 159,921 | — | plan? |
| May 21, 2015 SForm 4 → | May 26, 7:53 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 61,818 | $38.86 | $2,402,523 | 0 | −100% | plan? |
| May 21, 2015 MForm 4 → | May 26, 7:53 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 61,818 | $0.055 | $3,400 | 7,202 | — | plan? |
| May 21, 2015 SForm 4 → | May 21, 3:34 pm EDT | Stephen M DowDirector | 20,000 | $65.69 | $1,313,846 | 314,203 | −5.98% | plan? |
| May 20, 2015 SForm 4/A → | May 21, 6:30 pm EDT | Stephen M DowDirector, 10% Owner | 8,462 | $40.39 | $341,820 | 4,313,992 | −0.20% | plan? |
| May 19, 2015 SForm 4 → | May 21, 6:20 pm EDT | Larry BenedictSr. VP Finance | 20,000 | $38.86 | $777,196 | 663 | −96.8% | plan? |
| May 19, 2015 MForm 4 → | May 21, 6:20 pm EDT | Larry BenedictSr. VP Finance | 20,000 | $1.65 | $33,000 | 20,663 | — | plan? |
| May 19, 2015 SForm 4 → | May 21, 5:53 pm EDT | SRB Associates IX L.P. +210% Owner | 1,136,100 | $37.02 | $42,059,899 | 4,048,874 | −21.9% | plan? |
| May 14, 2015 SForm 4 → | May 18, 8:51 pm EDT | Clay B SiegallDirector | 38,181 | $37.62 | $1,436,495 | 4,444 | −89.6% | plan? |
| May 14, 2015 MForm 4 → | May 18, 8:51 pm EDT | Clay B SiegallDirector | 18,181 | $0.33 | $6,000 | 42,625 | — | plan? |
| May 1, 2015 SForm 4 → | May 5, 6:22 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $25.67 | $100,130 | 0 | −100% | plan? |
| May 1, 2015 MForm 4 → | May 5, 6:22 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| May 1, 2015 SForm 4 → | May 5, 6:18 pm EDT | John A LathamChief Scientific Officer | 4,545 | $25.67 | $116,663 | 208,988 | −2.13% | plan? |
| May 1, 2015 MForm 4 → | May 5, 6:18 pm EDT | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,533 | — | plan? |
| Apr 1, 2015 SForm 4 → | Apr 3, 6:02 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $27.43 | $106,995 | 0 | −100% | plan? |
| Apr 1, 2015 MForm 4 → | Apr 3, 6:02 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Apr 1, 2015 SForm 4 → | Apr 3, 5:58 pm EDT | Mark James LittonChief Business Officer | 7,500 | $27.41 | $205,553 | 74,359 | −9.16% | plan? |
| Mar 30, 2015 SForm 4 → | Apr 1, 8:36 pm EDT | John A LathamChief Scientific Officer | 19,045 | $29.54 | $562,518 | 208,988 | −8.35% | plan? |
| Mar 30, 2015 MForm 4 → | Apr 1, 8:36 pm EDT | John A LathamChief Scientific Officer | 19,045 | $0.385 | $7,332 | 213,533 | — | plan? |
| Mar 2, 2015 SForm 4 → | Mar 4, 5:35 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $26.25 | $102,357 | 0 | −100% | plan? |
| Mar 2, 2015 MForm 4 → | Mar 4, 5:35 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 3,900 | — | plan? |
| Mar 2, 2015 SForm 4 → | Mar 4, 5:32 pm EST | John A LathamChief Scientific Officer | 4,545 | $26.26 | $119,340 | 208,988 | −2.13% | plan? |
| Mar 2, 2015 MForm 4 → | Mar 4, 5:32 pm EST | John A LathamChief Scientific Officer | 4,545 | $0.385 | $1,750 | 213,533 | — | plan? |
| Jan 26, 2015 SForm 4 → | Jan 28, 6:01 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $28.01 | $109,237 | 0 | −100% | plan? |
| Jan 26, 2015 MForm 4 → | Jan 28, 6:01 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | $0.385 | $1,502 | 1,200 | — | plan? |
| Jan 26, 2015 SForm 4 → | Jan 28, 5:56 pm EST | Mark James LittonChief Business Officer | 7,500 | $28.18 | $211,334 | 81,859 | −8.39% | plan? |
| Jan 26, 2015 SForm 4 → | Jan 28, 5:54 pm EST | John A LathamChief Scientific Officer | 15,045 | $28.33 | $426,286 | 208,988 | −6.72% | plan? |
| Jan 26, 2015 MForm 4 → | Jan 28, 5:54 pm EST | John A LathamChief Scientific Officer | 15,045 | $0.385 | $5,792 | 216,133 | — | plan? |
| Jan 26, 2015 SForm 4 → | Jan 28, 5:51 pm EST | Randall C SchatzmanPresident and CEO, Director | 100,000 | $28.42 | $2,842,399 | 109,921 | −47.6% | plan? |
| Nov 28, 2014 AForm 4 → | Jan 28, 2015, 6:09 pm EST | Larry BenedictSr. VP Finance | 663 | $8.50 | $5,636 | 663 | — | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| May 27, 2016 MForm 4 → | Jun 1, 7:53 pm EDT | John A LathamChief Scientific Officer | 40,000 | — | — | 63,636 | — | |
| May 27, 2016 MForm 4 → | Jun 1, 7:49 pm EDT | Mark James LittonChief Business Officer | 25,000 | — | — | 25,000 | — | |
| May 26, 2016 AForm 4 → | Jun 2, 7:11 pm EDT | Clay B SiegallDirector | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 7:06 pm EDT | Heather PrestonDirector | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 7:00 pm EDT | Deepika PakianathanDirector, 10% Owner | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 6:54 pm EDT | Alan Bruce MontgomeryDirector | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 6:49 pm EDT | Stephen M DowDirector | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 6:45 pm EDT | Paul B ClevelandDirector | 15,000 | — | — | 15,000 | — | late |
| May 26, 2016 AForm 4 → | Jun 2, 6:42 pm EDT | Paul Rutherford CarterDirector | 15,000 | — | — | 15,000 | — | late |
| May 20, 2016 MForm 4 → | May 24, 8:13 pm EDT | Randall C SchatzmanPresident and CEO, Director | 10,000 | — | — | 48,181 | — | |
| Apr 14, 2016 MForm 4 → | Apr 18, 6:40 pm EDT | Randall C SchatzmanPresident and CEO, Director | 30,000 | — | — | 58,181 | — | |
| Mar 3, 2016 AForm 4 → | Mar 7, 8:37 pm EST | James B BucherSr. VP & General Counsel | 95,000 | — | — | 95,000 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:13 pm EST | Randal HasslerSVP, Pharmaceutical Ops | 75,000 | — | — | 75,000 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:11 pm EST | John A LathamChief Scientific Officer | 100,000 | — | — | 100,000 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:09 pm EST | Mark James LittonChief Business Officer | 50,000 | — | — | 50,000 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:08 pm EST | Randall C SchatzmanPresident and CEO, Director | 236,500 | — | — | 236,500 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:03 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 100,000 | — | — | 100,000 | — | |
| Jan 29, 2016 AForm 4 → | Feb 2, 7:00 pm EST | Larry BenedictSr. VP Finance | 40,000 | — | — | 40,000 | — | |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:40 pm EST | Mark James LittonChief Business Officer | 25,000 | — | — | 50,000 | — | |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:37 pm EST | John A LathamChief Scientific Officer | 10,000 | — | — | 30,909 | — | |
| Jan 4, 2016 MForm 4 → | Jan 6, 8:35 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | — | — | 20,000 | — | |
| Dec 1, 2015 MForm 4 → | Dec 3, 9:02 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 4,272 | — | — | 0 | — | |
| Dec 1, 2015 MForm 4 → | Dec 3, 9:00 pm EST | John A LathamChief Scientific Officer | 4,550 | — | — | 0 | — | |
| Dec 1, 2015 MForm 4 → | Dec 3, 8:59 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | — | — | 30,000 | — | |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:44 pm EST | John A LathamChief Scientific Officer | 4,545 | — | — | 4,550 | — | |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:42 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 4,272 | — | |
| Nov 2, 2015 MForm 4 → | Nov 4, 9:40 pm EST | Randall C SchatzmanPresident and CEO, Director | 10,000 | — | — | 40,000 | — | |
| Oct 1, 2015 MForm 4 → | Oct 5, 6:21 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 9,095 | — | |
| Oct 1, 2015 MForm 4 → | Oct 5, 6:16 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 8,172 | — | |
| Sep 30, 2015 AForm 4 → | Oct 2, 8:30 pm EDT | Paul B ClevelandDirector | 17,300 | — | — | 17,300 | — | |
| Sep 28, 2015 AForm 4 → | Sep 30, 6:22 pm EDT | Paul Rutherford CarterDirector | 30,000 | — | — | 30,000 | — | |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:19 pm EDT | Larry BenedictSr. VP Finance | 24,981 | — | — | 7,744 | — | |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:14 pm EDT | John A LathamChief Scientific Officer | 31,818 | — | — | 0 | — | |
| Sep 24, 2015 MForm 4 → | Sep 28, 6:11 pm EDT | Mark James LittonChief Business Officer | 12,764 | — | — | 7,690 | — | |
| Sep 1, 2015 MForm 4 → | Sep 3, 6:09 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 13,640 | — | |
| Sep 1, 2015 MForm 4 → | Sep 3, 6:01 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 12,072 | — | |
| Aug 26, 2015 AForm 4 → | Aug 27, 6:25 pm EDT | Paul B ClevelandDirector | 12,700 | — | — | 12,700 | — | |
| Aug 3, 2015 MForm 4 → | Aug 5, 6:27 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 18,185 | — | |
| Aug 3, 2015 MForm 4 → | Aug 5, 6:26 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 15,972 | — | |
| Jul 1, 2015 MForm 4 → | Jul 6, 6:05 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 19,872 | — | |
| Jul 1, 2015 MForm 4 → | Jul 6, 6:02 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 22,730 | — | |
| Jun 12, 2015 MForm 4 → | Jun 16, 6:15 pm EDT | Larry BenedictSr. VP Finance | 25,454 | — | — | 0 | — | |
| Jun 4, 2015 MForm 4 → | Jun 8, 7:05 pm EDT | Mark James LittonChief Business Officer | 25,000 | — | — | 75,000 | — | |
| Jun 4, 2015 MForm 4 → | Jun 8, 7:03 pm EDT | John A LathamChief Scientific Officer | 25,000 | — | — | 27,275 | — | |
| Jun 1, 2015 MForm 4 → | Jun 3, 8:04 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 23,772 | — | |
| Jun 1, 2015 MForm 4 → | Jun 3, 7:59 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 52,275 | — | |
| May 26, 2015 MForm 4 → | May 28, 6:15 pm EDT | Randall C SchatzmanPresident and CEO, Director | 50,000 | — | — | 50,000 | — | |
| May 21, 2015 MForm 4 → | May 26, 7:53 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 61,818 | — | — | 0 | — | |
| May 19, 2015 AForm 4/A → | May 21, 6:30 pm EDT | Stephen M DowDirector, 10% Owner | 6,350 | — | — | 6,350 | — | |
| May 19, 2015 MForm 4 → | May 21, 6:20 pm EDT | Larry BenedictSr. VP Finance | 20,000 | — | — | 25,454 | — | |
| May 19, 2015 AForm 4 → | May 21, 6:14 pm EDT | Clay B SiegallDirector | 6,350 | — | — | 6,350 | — | |
| May 19, 2015 AForm 4 → | May 21, 6:11 pm EDT | Heather PrestonDirector | 6,350 | — | — | 6,350 | — | |
| May 19, 2015 AForm 4 → | May 21, 6:09 pm EDT | Deepika PakianathanDirector, 10% Owner | 6,350 | — | — | 6,350 | — | |
| May 19, 2015 AForm 4 → | May 21, 6:07 pm EDT | Alan Bruce MontgomeryDirector | 6,350 | — | — | 6,350 | — | |
| May 19, 2015 AForm 4 → | May 21, 6:04 pm EDT | Gary BridgerDirector | 6,350 | — | — | 6,350 | — | |
| May 14, 2015 MForm 4 → | May 18, 8:51 pm EDT | Clay B SiegallDirector | 18,181 | — | — | 0 | — | |
| May 1, 2015 MForm 4 → | May 5, 6:22 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 27,672 | — | |
| May 1, 2015 MForm 4 → | May 5, 6:18 pm EDT | John A LathamChief Scientific Officer | 4,545 | — | — | 56,820 | — | |
| Apr 1, 2015 MForm 4 → | Apr 3, 6:02 pm EDT | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 31,572 | — | |
| Mar 30, 2015 MForm 4 → | Apr 1, 8:36 pm EDT | John A LathamChief Scientific Officer | 19,045 | — | — | 61,365 | — | |
| Mar 2, 2015 MForm 4 → | Mar 4, 5:35 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 3,900 | — | — | 35,472 | — | |
| Mar 2, 2015 MForm 4 → | Mar 4, 5:32 pm EST | John A LathamChief Scientific Officer | 4,545 | — | — | 80,410 | — | |
| Jan 26, 2015 AForm 4 → | Jan 28, 6:12 pm EST | Randal HasslerSVP, Manufacturing | 30,000 | — | — | 30,000 | — | |
| Jan 26, 2015 AForm 4 → | Jan 28, 6:09 pm EST | Larry BenedictSr. VP Finance | 30,000 | — | — | 30,000 | — | |
| Jan 26, 2015 AMForm 4 → | Jan 28, 6:01 pm EST | Jeffrey T L SmithSr. VP Translational Medicine | 53,900 | — | — | 39,372 | — | |
| Jan 26, 2015 AForm 4 → | Jan 28, 5:56 pm EST | Mark James LittonChief Business Officer | 35,000 | — | — | 35,000 | — | |
| Jan 26, 2015 AMForm 4 → | Jan 28, 5:54 pm EST | John A LathamChief Scientific Officer | 75,045 | — | — | 84,955 | — | |
| Jan 26, 2015 AForm 4 → | Jan 28, 5:51 pm EST | Randall C SchatzmanPresident and CEO, Director | 130,000 | — | — | 130,000 | — |